Details of Disease

General Information of Disease (ID: DIS34WJ5)

• Disease Name: Chronic fatigue syndrome
• Synonyms: myalgic encephalitis; Postviral fatigue syndrome; systemic exertion intolerance disease; myalgic encephalomyelitis; CFS; chronic fatigue syndrome; chronic fatigue immune dysfunction syndrome
• Disease Class: 8E49: Postviral fatigue syndrome
• Definition: A medical condition characterized by long-term fatigue and other symptoms that limit a person's ability to carry out ordinary daily activities.
• Disease Hierarchy:
  DIS6SVEE: Syndromic disease
  DISD715V: Hereditary neurological disease
  DIS093I0: Immunodeficiency
  DISXAP3G: Muscle tissue disorder
  DIS34WJ5: Chronic fatigue syndrome
• ICD Code:
  ICD-11: ICD-11: 8E49
  ICD-10: ICD-10: G93.3
  Expand ICD-11: '8E49
  Expand ICD-10: 'G93.3
• Disease Identifiers:
  MONDO ID: MONDO_0005404
  MESH ID: D015673
  UMLS CUI: C0015674
  MedGen ID: 5130
  Orphanet ID: 1983
  SNOMED CT ID: 51771007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Droxidopa	DM5YF4M	Approved	Small molecular drug	[1]
Norepinephrine	DMOUC09	Approved	Small molecular drug	[2]
Acetylcarnitine	DM4UE3K	Phase 4	Small molecular drug	[]

This Disease is Treated as An Indication in 1 Drugs in Phase 1 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rintatolimod	DMSDZ8U	Phase 1/2 Trial	Protein/peptide drug	[3]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Rintatolimid	DM574C8	Application submitted	NA	[4]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SPV-30	DMK23K4	Terminated	NA	[5]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 12 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
FURIN	TTH9WF6	Limited	Biomarker	[6]
ASIC3	TTLGDIS	Strong	Biomarker	[7]
DUT	TTH6MBO	Strong	Biomarker	[8]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[9]
HTR7	TTO9X1H	Strong	Biomarker	[10]
MASP2	TTR01E9	Strong	Altered Expression	[11]
NR3C1	TTOZRK6	Strong	Biomarker	[12]
NTRK3	TTXABCW	Strong	Biomarker	[13]
RNASEL	TT7V0K4	Strong	Genetic Variation	[14]
SERPINA6	TTJL8VG	Strong	Genetic Variation	[15]
TPH2	TT3KLDP	Strong	Altered Expression	[16]
TRPM3	TTO3TD8	Strong	Biomarker	[17]

This Disease Is Related to 16 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DBI	OT884QY9	Strong	Biomarker	[18]
DISC1	OT43AW4H	Strong	Genetic Variation	[19]
EMB	OT67E3Q1	Strong	Biomarker	[20]
ETV6	OTCZMG61	Strong	Genetic Variation	[13]
FANCM	OTNJG99Z	Strong	Biomarker	[21]
FCN1	OTK6ZHXH	Strong	Altered Expression	[11]
KLRC2	OTT4N86S	Strong	Biomarker	[22]
MYOG	OTPLJKFA	Strong	Altered Expression	[23]
NHS	OTKE8QAT	Strong	Biomarker	[24]
NPAS2	OTMRT2TS	Strong	Genetic Variation	[25]
NRSN1	OT1KKXC8	Strong	Biomarker	[26]
OAS2	OT64CCTM	Strong	Altered Expression	[27]
SESN1	OTSFDZWL	Strong	Biomarker	[28]
SIGLEC12	OTC36XP9	Strong	Genetic Variation	[29]
TMED2	OTBLO7RW	Strong	Biomarker	[26]
TPPP	OTCFMSUF	Strong	Biomarker	[26]

References

• [1] Droxidopa FDA Label
• [2] Norepinephrine FDA Label
• [3] ClinicalTrials.gov (NCT00215813) Ampligen in Chronic Fatigue Syndrome. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006633)
• [6] Psychometric Properties and Factor Structure of a Long and Shortened Version of the Cognitive and Behavioural Responses Questionnaire.Psychosom Med. 2018 Feb/Mar;80(2):230-237. doi: 10.1097/PSY.0000000000000536.
• [7] Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls.Psychosom Med. 2012 Jan;74(1):46-54. doi: 10.1097/PSY.0b013e31824152ed. Epub 2011 Dec 30.
• [8] Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.Clin Ther. 2019 May;41(5):848-863. doi: 10.1016/j.clinthera.2019.04.009. Epub 2019 Apr 28.
• [9] Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection.Clin Infect Dis. 2001 Dec 15;33(12):2080-1. doi: 10.1086/324357. Epub 2001 Nov 6.
• [10] Genetic evaluation of the serotonergic system in chronic fatigue syndrome.Psychoneuroendocrinology. 2008 Feb;33(2):188-97. doi: 10.1016/j.psyneuen.2007.11.001.
• [11] Transcriptional control of complement activation in an exercise model of chronic fatigue syndrome.Mol Med. 2009 Jan-Feb;15(1-2):34-42. doi: 10.2119/molmed.2008.00098. Epub 2008 Nov 10.
• [12] Glucocorticoid receptor DNA methylation and childhood trauma in chronic fatigue syndrome patients.J Psychosom Res. 2018 Jan;104:55-60. doi: 10.1016/j.jpsychores.2017.11.011. Epub 2017 Nov 20.
• [13] Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.Am J Surg Pathol. 2000 Jul;24(7):937-46. doi: 10.1097/00000478-200007000-00005.
• [14] Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease.Immunol Res. 2010 Dec;48(1-3):27-39. doi: 10.1007/s12026-010-8165-y.
• [15] Corticosteroid-binding globulin gene polymorphisms: clinical implications and links to idiopathic chronic fatigue disorders.Clin Endocrinol (Oxf). 2007 Aug;67(2):161-7. doi: 10.1111/j.1365-2265.2007.02890.x. Epub 2007 Jun 4.
• [16] The variation of the 5-hydroxytryptamine system between chronic unpredictable mild stress rats and chronic fatigue syndrome rats induced by forced treadmill running.Neuroreport. 2017 Aug 2;28(11):630-637. doi: 10.1097/WNR.0000000000000797.
• [17] Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.Front Immunol. 2019 Oct 31;10:2545. doi: 10.3389/fimmu.2019.02545. eCollection 2019.
• [18] Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.Psychoneuroendocrinology. 2013 Dec;38(12):2983-95. doi: 10.1016/j.psyneuen.2013.08.008. Epub 2013 Sep 6.
• [19] A functional polymorphism in the disrupted-in schizophrenia 1 gene is associated with chronic fatigue syndrome.Life Sci. 2010 May 8;86(19-20):722-5. doi: 10.1016/j.lfs.2010.03.007. Epub 2010 Mar 20.
• [20] Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain.AIDS Res Hum Retroviruses. 2012 Sep;28(9):1089-94. doi: 10.1089/AID.2011.0149. Epub 2012 Feb 21.
• [21] BLM prevents instability of structure-forming DNA sequences at common fragile sites.PLoS Genet. 2018 Nov 29;14(11):e1007816. doi: 10.1371/journal.pgen.1007816. eCollection 2018 Nov.
• [22] Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Front Immunol. 2018 May 9;9:1028. doi: 10.3389/fimmu.2018.01028. eCollection 2018.
• [23] Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome.PLoS One. 2015 Apr 2;10(4):e0122982. doi: 10.1371/journal.pone.0122982. eCollection 2015.
• [24] Important factors to consider when treating children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): perspectives of health professionals from specialist services.BMC Pediatr. 2017 Feb 1;17(1):43. doi: 10.1186/s12887-017-0799-7.
• [25] Convergent genomic studies identify association of GRIK2 and NPAS2 with chronic fatigue syndrome.Neuropsychobiology. 2011;64(4):183-94. doi: 10.1159/000326692. Epub 2011 Sep 9.
• [26] Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from Japanese patients with chronic fatigue syndrome.FEBS Lett. 1996 Jan 8;378(2):145-9. doi: 10.1016/0014-5793(95)01439-x.
• [27] Molecular signatures of peripheral blood mononuclear cells during chronic interferon- treatment: relationship with depression and fatigue.Psychol Med. 2012 Aug;42(8):1591-603. doi: 10.1017/S0033291711002868. Epub 2011 Dec 9.
• [28] Identifying illness parameters in fatiguing syndromes using classical projection methods.Pharmacogenomics. 2006 Apr;7(3):407-19. doi: 10.2217/14622416.7.3.407.
• [29] Maintenance of Chronic Fatigue Syndrome (CFS) in Young CFS Patients Is Associated with the 5-HTTLPR and SNP rs25531 A > G Genotype.PLoS One. 2015 Oct 16;10(10):e0140883. doi: 10.1371/journal.pone.0140883. eCollection 2015.